NEW YORK, Jan. 16, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Humacyte, Inc. (NASDAQ: HUMA).Shareholders who purchased shares of HUMA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/humacyte-inc-loss-submission-form/?id=123032&from=4CLASS PERIOD: May 10, 2024 to October 1 ...

NEW YORK, Jan. 14, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Humacyte, Inc. (NASDAQ: HUMA) between May 10, 2024 and October 17, 2024, both dates inclusive (the “Class Period”), of the important January 17, 2025 lead plaintiff deadline. SO WHAT: If you purchased Humacyte securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT ...

LOS ANGELES, Jan. 13, 2025 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Humacyte, Inc. ("Humacyte" or the "Company") (NASDAQ: HUMA) have opportunity to lead the securities fraud class action lawsuit.IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN HUMACYTE, INC. (HUMA), CLICK HERE BEFORE JANUARY 17, 2025 (THE LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT. What Is The Lawsuit About? The complaint filed alleges that, between Ma ...

Core Insights - Humacyte, Inc. has announced plans for the commercial launch of Symvess, a bioengineered human tissue designed for arterial replacement and repair, following FDA approval [2][6] - The company has established a highly experienced sales team to support the launch, with members having an average of over 15 years in medical device and biotech sales [3] - Symvess is priced at $29,500 per unit, with a Budget Impact Model indicating potential cost savings compared to current treatment options [4] FDA Approval and Market Readiness - The FDA granted full approval for Symvess on December 19, 2024, for use in adults with extremity arterial injury when urgent revascularization is needed [2] - Humacyte expects to begin product shipments early in the current quarter and is building product supply to support the market launch [2] Sales and Marketing Strategy - The sales team consists of ten members, all of whom are top achievers in their previous organizations, with experience in vascular and trauma surgery [3] - The team has a strong background in selling clinically differentiated technologies and regenerative therapies [3] Pricing and Cost Savings - Symvess is priced at $29,500 per unit, and the Budget Impact Model suggests that treating patients with Symvess may be less costly than using synthetic grafts or other alternatives [4] - Key cost savings are attributed to reduced rates of amputation and vascular conduit infection [4] Reimbursement and Financial Support - Humacyte submitted an NTAP application to CMS in October 2024, which, if approved, would provide additional payment to hospitals for costs associated with Symvess starting October 1, 2025 [5] Clinical Evidence and Applications - Symvess has shown positive results in clinical studies, including high rates of patency and low rates of amputation and infection [7] - The product has been used in various traumatic injury cases, including wartime injuries in Ukraine, demonstrating its versatility and effectiveness [6][7]

Class Action Lawsuit Details - A class action lawsuit has been filed against Humacyte, Inc (NASDAQ: HUMA) for purchasers of securities between May 10, 2024, and October 17, 2024 [4] - The lawsuit alleges that Humacyte made false and/or misleading statements and/or failed to disclose critical information regarding its Durham, North Carolina facility's non-compliance with good manufacturing practices, including quality assurance and microbial testing [7] - The lawsuit claims that the FDA's review of Humacyte's Biologics License Application (BLA) was delayed due to the need for remediation of these deficiencies, posing a substantial risk to FDA approval of Acellular Tissue Engineered Vessel (ATEV) for vascular trauma [7] - Investors allegedly suffered damages when the true details entered the market, as the defendants' positive statements about Humacyte's business, operations, and prospects were materially misleading and/or lacked a reasonable basis [7] Legal Representation and Deadlines - The Rosen Law Firm is reminding purchasers of Humacyte securities during the Class Period of the important January 17, 2025, lead plaintiff deadline [4] - Investors who purchased Humacyte securities during the Class Period may be entitled to compensation without payment of any out-of-pocket fees or costs through a contingency fee arrangement [4] - The Rosen Law Firm encourages investors to select qualified counsel with a track record of success in leadership roles, emphasizing its own achievements, including securing over $438 million for investors in 2019 and being ranked No 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017 [5] Participation in the Class Action - Investors can join the Humacyte class action by visiting the Rosen Law Firm's website or contacting Phillip Kim, Esq toll-free at 866-767-3653 or via email at case@rosenlegal com [2][6] - No class has been certified yet, and until a class is certified, investors are not represented by counsel unless they retain one Investors may select counsel of their choice or remain an absent class member [8]

NEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Humacyte, Inc. (NASDAQ: HUMA) between May 10, 2024 and October 17, 2024, both dates inclusive (the “Class Period”), of the important January 17, 2025 lead plaintiff deadline. SO WHAT: If you purchased Humacyte securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT ...

NEW YORK, Jan. 6, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Humacyte, Inc. (NASDAQ: HUMA).Shareholders who purchased shares of HUMA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/humacyte-inc-loss-submission-form/?id=120441&from=4 CLASS PERIOD: May 10, 2024 to October 1 ...

NEW YORK, Jan. 3, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Humacyte, Inc. ("Humacyte, Inc." or the "Company") (NASDAQ: HUMA) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Humacyte, Inc. investors who were adversely affected by alleged securities fraud between May 10, 2024 and October 17, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/humacyte-inc-lawsuit-sub ...

NEW YORK, Dec. 30, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Humacyte, Inc. (NASDAQ: HUMA).Shareholders who purchased shares of HUMA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/humacyte-inc-loss-submission-form/?id=118940&from=4 CLASS PERIOD: May 10, 2024 to October ...

NEW YORK, Dec. 27, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Humacyte, Inc. ("Humacyte" or the "Company") (NASDAQ: HUMA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.The class action concerns whether Humacyte and certain of its officers an ...